These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38432417)
1. A modified diffusion-weighted magnetic resonance imaging-based model from the radiologist's perspective: improved performance in determining the surgical resectability of advanced high-grade serous ovarian cancer. Lu J; Guo Q; Zhang Y; Zhao S; Li R; Fu Y; Feng Z; Wu Y; Li R; Li X; Qiang J; Wu X; Gu Y; Li H Am J Obstet Gynecol; 2024 Jul; 231(1):117.e1-117.e17. PubMed ID: 38432417 [TBL] [Abstract][Full Text] [Related]
2. Diffusion-Weighted Magnetic Resonance Imaging and Morphological Characteristics Evaluation for Outcome Prediction of Primary Debulking Surgery for Advanced High-Grade Serous Ovarian Carcinoma. Li H; Lu J; Deng L; Guo Q; Lin Z; Zhao S; Ge H; Qiang J; Gu Y; Liu Z J Magn Reson Imaging; 2023 May; 57(5):1340-1349. PubMed ID: 36054024 [TBL] [Abstract][Full Text] [Related]
3. Prediction of postoperative residual primary ovarian neoplasm or metastatic lesion close to rectum of serous ovarian carcinoma based on clinical and MR T1-DEI features. Zhang W; Li J; Chen Q; Jin H; Zhou L; Liu L Acta Radiol; 2024 Sep; 65(9):1153-1163. PubMed ID: 39043176 [TBL] [Abstract][Full Text] [Related]
4. Time-dependent diffusion MRI-based microstructural mapping for differentiating high-grade serous ovarian cancer from serous borderline ovarian tumor. Cao Y; Lu Y; Shao W; Zhai W; Song J; Zhang A; Huang S; Zhao X; Cheng W; Wu F; Chen T Eur J Radiol; 2024 Sep; 178():111622. PubMed ID: 39018648 [TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516 [TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Boerner T; Tanner E; Filippova O; Zhou QC; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Gardner GJ; Sonoda Y; Abu-Rustum NR; Zivanovic O; Long Roche K; Afonso AM; Fischer M; Chi DS Gynecol Oncol; 2021 Jan; 160(1):51-55. PubMed ID: 33213899 [TBL] [Abstract][Full Text] [Related]
7. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers. Wang J; Liu L; Pang H; Liu L; Jing X; Li Y Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992 [TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients. Feng Z; Fu Y; Li R; Li H; Lu J; Chen X; Ju X; Wu X; Wen H Gynecol Oncol; 2023 Jul; 174():142-147. PubMed ID: 37207498 [TBL] [Abstract][Full Text] [Related]
9. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. Filippova OT; Boecking K; Broach V; Gardner GJ; Sonoda Y; Chi DS; Zivanovic O; Long Roche K Gynecol Oncol; 2024 Aug; 187():80-84. PubMed ID: 38735143 [TBL] [Abstract][Full Text] [Related]
10. Surgical evidence-based comparison of [ Li X; Lv X; Quan Z; Han T; Tang Y; Liu Y; Wang M; Li G; Ye J; Wang J; Lan X; Zhang X; Li M; Liu S; Kang F; Wang J Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1773-1785. PubMed ID: 38197954 [TBL] [Abstract][Full Text] [Related]
11. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
12. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614 [TBL] [Abstract][Full Text] [Related]
14. Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer. Uehara T; Matsuzaki J; Yoshida H; Ogawa Y; Miura J; Fujimiya H; Yamamoto Y; Kawauchi J; Takizawa S; Yonemori K; Sakamoto H; Kato K; Ishikawa M; Ochiya T Jpn J Clin Oncol; 2024 Aug; 54(8):917-925. PubMed ID: 38651188 [TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance Imaging and Diffusion Weighted Imaging-Based Histogram in Predicting Mesenchymal Transition High-Grade Serous Ovarian Cancer. Cai SQ; Song ZY; Wu MR; Lu JJ; Sun WW; Wei F; Li HM; Qiang JW; Li YA; Zhu J; Zhou JJ; Zeng MS Acad Radiol; 2023 Jun; 30(6):1118-1128. PubMed ID: 35909051 [TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation. Ono T; Kishimoto K; Tajima S; Maeda I; Takagi M; Suzuki N; Mimura H Acta Radiol; 2020 Jul; 61(7):992-1000. PubMed ID: 31698924 [TBL] [Abstract][Full Text] [Related]
17. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Engbersen MP; Van' T Sant I; Lok C; Lambregts DMJ; Sonke GS; Beets-Tan RGH; van Driel WJ; Lahaye MJ Eur J Radiol; 2019 May; 114():146-151. PubMed ID: 31005166 [TBL] [Abstract][Full Text] [Related]
18. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879 [TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma. Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928 [TBL] [Abstract][Full Text] [Related]
20. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]